53 139

Cited 0 times in

위암환자에서 예후인자로서 EGFR,p21(ras oncogene product) 및 p53의 연구

DC Field Value Language
dc.contributor.author노성훈-
dc.contributor.author최승호-
dc.date.accessioned2023-07-12T00:20:24Z-
dc.date.available2023-07-12T00:20:24Z-
dc.date.issued1994-04-
dc.identifier.issn1226-0053-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195029-
dc.description.abstractThere are several evidences that cancer arise as the result of multiple alterations of gene. and many attempts were made recently to understand the true role of oncogene, growth factor and its receptor, and suppressor gene as a prognostic indicator. To determine whether alterations in EGFR, ras oncogene product and p53 are associated with prognosis in gastric carcinoma, the analysis was performed on paraffin embedded tissues of 119 primary gastric carcinomas by an immunohistochemical assay using LSAB(labelled streptavidin biotin) method. EGFR was positive in 53 cases(44.5%), ras oncogene product in 21 (17.6%), and p53 in 39(32.8%). The 5-year survival rate was 57.8% in EGFR positive and 71.3% in EGFR negative, especially of the patients with serosal invasion, 44.2% in EGFR positive and 69.6% in EGFR negative(p<0.05). Ras oncogene product positive and negative had 5 years survival rate of 47.9% and 60.0% in each, and in stage II, the survival difference was more distint. The 5 year survival rate in p53 positive and p53 negative were 56.7% and 68.9% respectively(p>0.05). In patients with stage II or without serosal invasion, there was slightly survival difference between p53 positive and p53 negative. So we conclud that EGFR and ras oncogene expression are significantly associated with worse prognosis in gastric carcinomas, especially, in case of serosal invasion or stage III. Although there was no significant difference in survival rate according to p53, we suggested that p53 may be the prognostic indicator in patients with stage II or no serosal invasion.-
dc.description.statementOfResponsibilityopen-
dc.publisher대한외과학회-
dc.relation.isPartOfJOURNAL OF THE KOREAN SURGICAL SOCIETY (대한외과학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title위암환자에서 예후인자로서 EGFR,p21(ras oncogene product) 및 p53의 연구-
dc.title.alternativeStudy of EGFR, ras Oncogene Product p53 as a Prognostic Factor in Patients with Gastric Carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthor민진식-
dc.contributor.googleauthor이희대-
dc.contributor.googleauthor이기범-
dc.contributor.googleauthor최승호-
dc.contributor.googleauthor박찬일-
dc.contributor.googleauthor노성훈-
dc.contributor.localIdA01281-
dc.contributor.localIdA04102-
dc.relation.journalcodeJ01893-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.affiliatedAuthor노성훈-
dc.contributor.affiliatedAuthor최승호-
dc.citation.volume46-
dc.citation.number4-
dc.citation.startPage502-
dc.citation.endPage510-
dc.identifier.bibliographicCitationJournal of the Korean Surgical Society (대한외과학회지), Vol.46(4) : 502-510, 1994-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.